Medicare Part D plans can now cover weight-loss medications including Wegovy and Zepbound for beneficiaries with obesity, marking a significant expansion of prescription drug benefits.
The change reflects growing recognition of obesity as a chronic disease rather than a lifestyle condition, aligning Medicare coverage with newer medical guidelines.
Not all Part D plans include these medications on their formularies, so beneficiaries should check their plan’s covered drug list during enrollment periods.
Out-of-pocket costs vary by plan and may be affected by the Part D deductible and coverage gap phase. Beneficiaries taking these medications should review their plan annually.